Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies

NCT07270263 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma
Leukemia
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Venous Thromboembolic Disease
VTE (Venous Thromboembolism)
PE - Pulmonary Embolism
Hematologic Malignacies

Interventions

DRUG: Apixaban
DRUG: Rivaroxaban
DRUG: low molecular weight heparin (enoxaparin sodium)

Sponsor

Medical University of Gdansk